Bacillus clausii (Enterogermina)
Bacillus clausii is a spore-forming probiotic bacteria that produces antimicrobial peptides and organic acids to restore gut microbiome balance. It works by competing with pathogenic bacteria for colonization sites while enhancing intestinal barrier function through tight junction protein regulation.
Origin & History
Bacillus clausii is a spore-forming probiotic bacterium that is naturally found in soil and water. It is produced through fermentation and used in various probiotic supplements to support digestive health.
Historical & Cultural Context
Traditionally, Bacillus clausii has been used in various cultures to promote digestive health and treat gastrointestinal disturbances. Its use as a probiotic supplement has gained popularity in recent years.
Health Benefits
- Supports digestive health by balancing gut flora, reducing symptoms of IBS by up to 50% in clinical trials. It enhances nutrient absorption by maintaining a healthy gut lining. - Boosts immune function by stimulating the production of antibodies, helping the body fend off infections more effectively. - Reduces inflammation by modulating cytokine production, which can decrease chronic disease risk. - Enhances mental clarity by influencing the gut-brain axis, potentially improving mood and cognitive function. - Aids in lactose digestion by producing lactase, allowing better tolerance for dairy products. - Promotes skin health by reducing gut inflammation, which can lead to clearer skin. - Supports respiratory health by modulating immune responses, reducing the incidence of respiratory infections.
How It Works
Bacillus clausii produces bacteriocins and organic acids that inhibit pathogenic bacterial growth while promoting beneficial microflora colonization. The strain enhances intestinal barrier integrity by upregulating claudin-1 and occludin tight junction proteins. It also stimulates secretory IgA production through interaction with Peyer's patches and dendritic cells in gut-associated lymphoid tissue.
Scientific Research
Research on Bacillus clausii includes randomized controlled trials (RCTs) demonstrating its efficacy in reducing the duration of diarrhea and supporting gut health. Meta-analyses also support its use in restoring intestinal flora balance.
Clinical Summary
Clinical trials demonstrate Bacillus clausii reduces IBS symptom severity by up to 50% in studies involving 200+ participants over 8-12 week periods. Randomized controlled trials show significant improvements in stool consistency and abdominal pain scores compared to placebo. Multiple studies confirm its effectiveness in preventing antibiotic-associated diarrhea, with success rates of 70-80%. However, most trials are relatively small-scale and additional large-scale studies would strengthen the evidence base.
Nutritional Profile
Bacillus clausii (Enterogermina) is a spore-forming probiotic bacterium with negligible direct macronutrient contribution at therapeutic doses (typically 2×10⁹ spores per 5mL vial). Macronutrient content per standard dose: protein <0.01g, carbohydrates <0.01g, fat <0.01g, calories ~0 kcal. The primary bioactive components are the bacterial spores themselves and their metabolic byproducts. Key bioactive compounds include: (1) Bacteriocin-like inhibitory substances (BLIS) that suppress pathogenic bacteria; (2) Short-chain fatty acids (SCFAs) produced during fermentation, particularly butyrate, acetate, and propionate, which fuel colonocyte health; (3) Biosurfactants with antimicrobial properties; (4) Exopolysaccharides (EPS) that modulate mucosal immunity. B. clausii strains (O/C, N/R, T, SIN) are known to synthesize B-group vitamins including riboflavin (B2, ~0.3–0.8 µg per 10⁹ spores), folic acid (B9, trace levels ~0.1–0.2 µg per 10⁹ spores), and pyridoxine (B6, trace). Antibiotic-resistance genes in specific strains allow survival alongside antibiotic therapy. Bioavailability note: spores resist gastric acid (stable at pH 2–3) and bile salts, achieving >85% intestinal delivery efficiency, where they germinate into vegetative cells and exert metabolic activity. No significant dietary fiber, minerals, or fat-soluble vitamins are contributed at standard dosing.
Preparation & Dosage
The recommended dosage is typically one to two vials per day. Consult a healthcare provider before use.
Synergy & Pairings
Lactobacillus rhamnosus, Bifidobacterium longum, Saccharomyces boulardii
Safety & Interactions
Bacillus clausii is generally well-tolerated with minimal reported side effects, though mild bloating may occur during initial use. No significant drug interactions have been documented, though it should be taken 2-3 hours apart from antibiotics to maintain viability. Immunocompromised individuals should consult healthcare providers before use due to theoretical infection risk. Safety during pregnancy and breastfeeding has not been extensively studied, warranting medical supervision.